Palliative care in patients with brain metastases

Current Opinion in Oncology

Volumn 17, Issue 6, 2005, Pages 588-592

  Taillibert, Sophie ^a   Delattre, Jean Yves ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Best supportive care; Brain metastases; Central nervous system metastases; Palliative care

Indexed keywords

17 METHYLNALTREXONE; AMITRIPTYLINE; ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; APREPITANT; BACLOFEN; CARBAMAZEPINE; CISPLATIN; CLONAZEPAM; CORTICOSTEROID; DEXAMETHASONE; ETIRACETAM; GABAPENTIN; IMMUNOSUPPRESSIVE AGENT; LAMOTRIGINE; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; ONDANSETRON; OPIATE; PHENYTOIN; RECOMBINANT ERYTHROPOIETIN; SEROTONIN ANTAGONIST; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; WARFARIN;

ACUTE DISEASE; ADRENAL INSUFFICIENCY; ANEMIA; ANOREXIA; ANXIETY DISORDER; ARTHRALGIA; ASEPTIC NECROSIS; ASTHENIA; BLEEDING; BRAIN DISEASE; BRAIN EDEMA; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANDIDIASIS; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DEEP VEIN THROMBOSIS; DEPRESSION; DIABETES MELLITUS; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DYSPHAGIA; ELECTROLYTE DISTURBANCE; EPILEPSY; FATIGUE; FEBRILE NEUTROPENIA; HEADACHE; HEMATOLOGIC DISEASE; HERPES ZOSTER; HUMAN; INFECTION; INSOMNIA; MENTAL DISEASE; MOOD DISORDER; MOTOR DYSFUNCTION; MYALGIA; MYOPATHY; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NEUROTOXICITY; NEUTROPENIA; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PAIN; PALLIATIVE THERAPY; PATHOGENESIS; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; PSYCHOSIS; REVIEW; SIDE EFFECT; SOMNOLENCE; STOMACH DISEASE; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TOXICITY; TREMOR; VASOGENIC EDEMA; VEIN THROMBOSIS; VOMITING;

ADRENAL CORTEX HORMONES; ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; BRAIN EDEMA; BRAIN NEOPLASMS; EPILEPSY; HUMANS; PAIN; PALLIATIVE CARE; RADIOTHERAPY; VENOUS THROMBOSIS;

EID: 27644594699     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000183673.15133.e2     Document Type: Review

References (37)

1. Pruitt AA. Treatment of medical complications in patients with brain tumors. Curr Treat Neurol 2005; 7:323-336. An excellent review of the medical treatment of patients with cerebral metastases and brain tumors.
2. El Kamar FG, Posner JB. Brain metastases. Semin Neurol 2004; 24: 347-362. An extensive and comprehensive review on the specific treatment that are currently available and on symptomatic care in patients with brain metastases.
3. Taillibert S, Laigle-Donadey F, Sanson S. Palliative care in patients with primary brain tumors. Curr Opin Oncol 2004; 16:587-592. A review on supportive care in patients with brain tumor, including the management of the medical complications and psychological issues.
4. Brown JE, Lester J, Ellis S, et al. Can an annual infusion of zoledronic acid protect against cancer-treatment induced bone loss? Proc Am Soc Clin Oncol 2005; 23:734s.
5. Brandes AA, Tososni A, Basso U, et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol 2004; 22:4779-4786.
6. Pardos MD, Yung WK, Jaeckle KA, et al. Phase I trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-oncol 2004; 6:44-54.
7. Caraceni A, Zecca E, Bonezzi C, et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin cancer Pain Study Group. J Clin Oncol 2004; 22:2909-2917.
8. Thomas J, Lipman A, Slatkin N, et al. A phase III double-blind placebo controlled trial methylnaltrexone for opioid-induced constipation in advanced medical illness. Proc Am Soc Clin Oncol 2005; 23:729s.
9. Aapro MS, Schmoll HJ, Poli-Bigelli S, et al. Comparison of aprepitant combination regimen with 4-day ondensetron + 4-day dexamethasone for prevention of acute and delayed nausea/vomiting after cisplatin chemotherapy. Proc Am Soc Clin Oncol 2005; 23:730s.
10. van den Bosch J, van de Werf PR, Sleeboom HP, et al. Improvements in anemia management with epoietin alpha: a Dutch survey. Proc Am Soc Clin Oncol 2005; 23:760s.
11. Rossi G, Glaspy J, Lyman G, et al. Are there clinical benefits associated with treatment of mild chemotherapy-induced anemia? a systematic review. Proc Am Soc Clin Oncol 2005; 23:777s.
12. Schwartzberg L, Houts AC, Fortner BV, et al. Mild anemia is associated with greater symptom burden and reduced quality of life in cancer patients. Proc Am Soc Clin Oncol 2005; 23:759s.
13. Henry DH. Epoetin alfa for the treatment of cancer- and chemotherapy-related anaemia: product review and update. Expert Opin Pharmacother 2005; 6: 295-310.
14. Chang J, Couture F, Young S, et al. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 2005; 23:2597-2605.
15. Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005; 23:2606-2617.
16. Patton J, Reeves T, Wallace J. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice. Oncologist 2004; 9:451-458.
17. Waltzman RJ, Croot C, Williams D, et al. Final hematologic results: epoietin alpha 40 000 U QW vs darbepoietin alpha 200 microg Q2W in anemic cancer patients receiving chemotherapy. Proc Am Soc Clin Oncol 2005; 23:736s.
18. Glaspy J, Berg R, Tomita D, et al. Final results of a phase 3, randomized, open-label study of darbepoetin alfa 200 mcg every 2 weeks (Q2W) versus epoetin alfa 40,000 U weekly (QW) in patients with chemotherapy-induced. Proc Am Soc Clin Oncol 2005; 23:760s.
19. Boccia A, Liu D, Silberstein P, et al. Evaluating the effectiveness of darbepoetin alfa 300 mcg Q3W for the treatment of chemotherapy-induced anemia. Proc Am Soc Clin Oncol 2005; 23:761s.
20. Cortesi E, Ricci S, Ucci G, et al. Randomized phase III study comparing standard TIW and weekly dosage of epoietin alpha with 2 weeks loading dose: preliminary results. Proc Am Soc Clin Oncol 2005; 23:782s.
21. Chang J, Phippard L, Sharma D, et al. A phase II randomized trial of three loading doses of epoietin alfa followed by every three-week dosing in cancer patients receiving chemotherapy. Proc Am Soc Clin Oncol 2005; 23:783s.
22. Canon J-L, Vansteenkiste J, Bodoky J, et al. Final results of a randomized, double-blind, active-controlled trial of darbepoietin alfa administered once every 3 weeks for the treatment of anemia in patients receiving multicycle chemotherapy. Proc Am Soc Clin Oncol 2005; 23:799s.
23. Fastenau J, Meisoglu A, Peake C, et al. Dosing and outcomes study of erythropoiesis-stimulating therapies-D.O.S. Proc Am Soc Clin Oncol 2005; 23: 551s.
24. Lower E, Fleishman S, Cooper A, et al. A phase III, randomized placebo-controlled trial of the safety and efficacy of d-MPH as new treatment of fatigue and 'chemobrain' in adult cancer patients. Proc Am Soc Clin Oncol 2005; 23:729s.
25. Rorth M, Andersen C, Quist M, et al. Health benefits of a multidimensional exercise program for cancer patients undergoing chemotherapy. Proc Am Soc Clin Oncol 2005; 23:731s.
26. Bruera E, Driver L, Valero V, et al. Patient controlled methylphenidate for cancer related fatigue: a randomized controlled trial. Proc Am Soc Clin Oncol 2005; 23:740s.
27. Morrow GR, Gillies LJ, Hickok JT, et al. The positive effect of the psychostimulant modafinil on fatigue from cancer that persists after treatment is completed. Proc Am Soc Clin Oncol 2005; 23:732s.
28. Maiese K, Li F, Zhong Chong Z. Erythropoietin in the brain: can the promise to protect be fulfilled? Trends Pharmacol Sci 2004; 25:577-583. Interesting review on a promising agent on potential great interest in the area of neuro-protection.
29. Marti HH. Review: Erythropietin and the hypoxic brain. J Exp Biol 2004; 207: 3233-3242. This review highlights the role of erythropoietin in brain hypoxia and its potential neuroprotective activity in that area.
30. Grasso G, Sfacteria A, Cerami A, et al. Erythropoietin as a tissue-protective cytokine in brain injury: what do we know and where do we go? Neuroscientist 2004; 10:93-98. Interesting review on the potential neuroprotective role of erythroprotein.
31. Genc S, Koroglu TF, Genc K. Erythropoietin as a novel neuroprotectant. Restor Neurol Neurosci 2004; 22:105-119. Interesting review on the potential neuroprotective role of erythropoietin.
32. Malhotra S, Nijhawan S, Rosenbaum DM. Erythropoietin as a protective factor for the brain. Curr Atheroscler Rep 2004; 6:301-306. Interesting review on the potential neuroprotective role of erythropoietin. Interesting review on the potential neuroprotective role of erythropoietin.
33. Ehrenreich H, Aust C, Krampe H, et al. Erythropoietin: novel approaches to neuroprotection in human brain disease. Metab Brain Dis 2004; 19: 195-206. Interesting review on the potential neuroprotective role of erythropoietin.
34. Banks WA, Jumbe NL, Farrell CL, et al. Passage of erythropoietic agents across the blood-brain barrier: a comparison of human and murine erythropoietin and the analog darbopoietin alfa. Eur J Pharmacol 2004; 505:93-101. Original study assessing the passage of currently available erythropoietic agents across the BBB for future application as neuro-protectants.
35. Kuderer NM, Crawford J, Dale DC, et al. Meta-analysis of prophylactic granulocyte colony-stimulating factor (G-CSF) in cancer patients receiving chemotherapy. Proc Am Soc Clin Oncol 2005; 23:758s.
36. Meza LA, Charu V, Campos L, et al. Pegfilgrastim and filgrastim patterns of use in community oncology practices: results of the ACCEPT study. Proc Am Soc Clin Oncol 2005; 23:556s.
37. Elting L, Lu C, Escalante C, et al. Safety and effectiveness of outpatient therapy in 596 low-risk patients with febrile neutropenia. Proc Am Soc Clin Oncol 2005; 23:758s.